Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of OBE022 added-on to atosiban, after oral administration in pregnant women with threatened spontaneous preterm labour

Next Previous
Trial Profile

A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of OBE022 added-on to atosiban, after oral administration in pregnant women with threatened spontaneous preterm labour

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ebopiprant (Primary) ; Atosiban
  • Indications Preterm labour
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PROLONG
  • Sponsors ObsEva

    • Most Recent Events

    • 02 Jul 2021 According to an ObsEva media release, data from this study will be presented at the Society for Reproductive Investigation (SRI) 68th Annual Meeting
    • 10 Jun 2021 Results presented in an ObsEva Media Release.
    • 10 Jun 2021 According to an ObsEva media release, data announced at the Royal College of Obstetricians and Gynecologists (RCOG) Virtual World Congress 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top